Extraction With Sweat-Sebum Emulsion as a New Test Method for Leachables in Patch-Based Medical Devices, Illustrated by Assessment of Isobornylacrylate (IBOA) in Diabetes Products.

IBOA ISO 10993 KeratinoSens assay glucose monitoring leachables medical device sebum skin irritation skin sensitization sweat

Journal

Journal of diabetes science and technology
ISSN: 1932-2968
Titre abrégé: J Diabetes Sci Technol
Pays: United States
ID NLM: 101306166

Informations de publication

Date de publication:
07 2021
Historique:
pubmed: 3 3 2020
medline: 29 10 2021
entrez: 3 3 2020
Statut: ppublish

Résumé

The increasing offering of patch-based medical devices is accompanied by growing numbers of reported adverse skin reactions. Procedures for testing leachables according to ISO 10993 may not be optimal for lipophilic substances that can be mobilized on skin by sweat and sebum. We propose an improved extraction method for targeted analysis of leachables using low volumes of a sweat-sebum emulsion. The approach is illustrated by the analysis of isobornylacrylate (IBOA), a compound found in some devices and suspected for allergenic potential. Three patch-based products were tested: an implantable device for continuous glucose monitoring (CGM), an intermittently scanned CGM (isCGM) device, and a micro-insulin pump. Quantification of IBOA was performed by gas chromatography and allergenic potential of IBOA levels was assessed by the KeratinoSens cell assay. Different combinations were used for extraction solvent (isopropanol, 5% ethanol-water solution, and sweat-sebum emulsion), extraction volumes (complete immersion vs partial immersion in 2 mm of solvent), and extraction time (3, 5, and 14 days). Isobornylacrylate was only found in the isCGM device. About 20 mg/L IBOA were eluted after 3 days in isopropanol but only about 1 mg/L in ethanol-water. Sweat-sebum emulsion dissolves IBOA better and gives a more stable solution than ethanol-water. Decomposition of IBOA solutions requires adjusted extraction timing or correction of results. In the sweat-sebum extract, IBOA levels were about 20 mg/L after 3 days and about 30 mg/L after 5 days, clearly above the threshold found in the KerationSens assay for keratinocyte activation (10 mg/L). Extraction by low volumes of sweat-sebum emulsion can be a superior alternative for the targeted simulating-use assessment of leachables in patch-based medical devices.

Sections du résumé

BACKGROUND
The increasing offering of patch-based medical devices is accompanied by growing numbers of reported adverse skin reactions. Procedures for testing leachables according to ISO 10993 may not be optimal for lipophilic substances that can be mobilized on skin by sweat and sebum. We propose an improved extraction method for targeted analysis of leachables using low volumes of a sweat-sebum emulsion. The approach is illustrated by the analysis of isobornylacrylate (IBOA), a compound found in some devices and suspected for allergenic potential.
METHOD
Three patch-based products were tested: an implantable device for continuous glucose monitoring (CGM), an intermittently scanned CGM (isCGM) device, and a micro-insulin pump. Quantification of IBOA was performed by gas chromatography and allergenic potential of IBOA levels was assessed by the KeratinoSens cell assay. Different combinations were used for extraction solvent (isopropanol, 5% ethanol-water solution, and sweat-sebum emulsion), extraction volumes (complete immersion vs partial immersion in 2 mm of solvent), and extraction time (3, 5, and 14 days).
RESULTS
Isobornylacrylate was only found in the isCGM device. About 20 mg/L IBOA were eluted after 3 days in isopropanol but only about 1 mg/L in ethanol-water. Sweat-sebum emulsion dissolves IBOA better and gives a more stable solution than ethanol-water. Decomposition of IBOA solutions requires adjusted extraction timing or correction of results. In the sweat-sebum extract, IBOA levels were about 20 mg/L after 3 days and about 30 mg/L after 5 days, clearly above the threshold found in the KerationSens assay for keratinocyte activation (10 mg/L).
CONCLUSION
Extraction by low volumes of sweat-sebum emulsion can be a superior alternative for the targeted simulating-use assessment of leachables in patch-based medical devices.

Identifiants

pubmed: 32115999
doi: 10.1177/1932296820908656
pmc: PMC8258535
doi:

Substances chimiques

Acrylates 0
Blood Glucose 0
Camphanes 0
Emulsions 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

792-800

Références

Contact Dermatitis. 2019 Sep;81(3):161-166
pubmed: 31206704
Toxicol Appl Pharmacol. 2011 Jan 15;250(2):87-95
pubmed: 20950635
Contact Dermatitis. 2019 Dec;81(6):432-437
pubmed: 31385313
Contact Dermatitis. 2018 Aug;79(2):76-80
pubmed: 29635853
Arch Toxicol. 2015 Oct;89(10):1645-68
pubmed: 26194644
Med Device Technol. 2000 Oct;11(8):8-11
pubmed: 11185190
J Diabetes Sci Technol. 2018 May;12(3):630-633
pubmed: 29542347
Trends Mol Med. 2004 Nov;10(11):549-57
pubmed: 15519281
Toxicol In Vitro. 2010 Sep;24(6):1790-6
pubmed: 20599493
Ther Adv Endocrinol Metab. 2019 Jul 25;10:2042018819865399
pubmed: 31384420
J Asthma Allergy. 2017 Jan 18;10:9-15
pubmed: 28176912
Exp Physiol. 2000 Nov;85(6):869-75
pubmed: 11187982
Adv Healthc Mater. 2018 Aug;7(15):e1800275
pubmed: 29757494
Environ Toxicol Chem. 2010 Mar;29(3):730-41
pubmed: 20821501
Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):2040-5
pubmed: 14764894
Contact Dermatitis. 2017 Dec;77(6):367-373
pubmed: 28804907
Sci Total Environ. 2019 Jul 1;672:798-805
pubmed: 30978542
Diabetes Technol Ther. 2019 Oct;21(10):538-545
pubmed: 31335203
Contact Dermatitis. 2017 Dec;77(6):426-429
pubmed: 29164694
Diabetes Technol Ther. 2018 Aug;20(8):541-549
pubmed: 30067410
J Diabetes Investig. 2019 Sep;10(5):1382-1384
pubmed: 30758915
Contact Dermatitis. 2016 Feb;74(2):124-5
pubmed: 26763993
Toxicol In Vitro. 2006 Dec;20(8):1265-83
pubmed: 16860531
Regul Toxicol Pharmacol. 2013 Dec;67(3):531-5
pubmed: 24140884
J Pharm Biomed Anal. 2014 Mar;90:139-47
pubmed: 24378610
Lancet Digit Health. 2019 May;1(1):e17-e25
pubmed: 33323237
Contact Dermatitis. 2018 Nov;79(5):320-321
pubmed: 30039529
Diabetes Ther. 2019 Apr;10(2):333-340
pubmed: 30737675
Biomater Sci. 2018 Jul 24;6(8):2025-2053
pubmed: 29968869
Diabetes Metab J. 2019 Aug;43(4):383-397
pubmed: 31441246
Diabetes Technol Ther. 2019 Apr;21(4):215-221
pubmed: 30943072
Diabetes Technol Ther. 2019 Oct;21(10):533-537
pubmed: 31287728
Med Device Technol. 2004 Jun;15(5):15-8
pubmed: 15285481

Auteurs

Herbert Fink (H)

Roche Diabetes Care GmbH, Mannheim, Germany.

Nuno M de Barros Fernandes (NM)

Roche Diabetes Care GmbH, Mannheim, Germany.

Jörg Weissmann (J)

Roche Diabetes Care GmbH, Mannheim, Germany.

Manfred Frey (M)

Steinbeis Innovationszentrum für Zellkulturtechnik, Mannheim, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH